This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.Find sources: "Somatrem" – news · newspapers · books · scholar · JSTOR (June 2019) (Learn how and when to remove this template message)
Clinical data
Trade namesProtropin
AHFS/Drugs.comMicromedex Detailed Consumer Information
ATC code
CAS Number
  • none
Chemical and physical data
Molar mass22256.26 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Somatrem, sold under the brand name Protropin, is an analogue of growth hormone (GH).[1]

Somatrem is a recombinant human growth hormone used for the treatment of short stature due to decreased or absent secretion of endogenous growth hormone. Somatrem was first marketed under the brand name Protropin by Genentech in 1985.[2] It differs from endogenous growth hormone by the addition of an extra methionine at the N-terminus[3][circular reference]. Somatrem has largely been replaced by somatropin, marketed by several companies including by Genentech as the brand Nutropin.


  1. ^ Flodh H (1987). "Present situation worldwide regarding the use and clinical experience of Somatonorm (somatrem)". Acta Paediatrica Scandinavica. Supplement. 331: 1–4. doi:10.1111/j.1651-2227.1987.tb17089.x. PMID 3300150. S2CID 20410776.
  2. ^ "Genentech: Press Releases - Friday, Oct 18, 1985".
  3. ^ Growth hormone therapy#cite note-32